Gene Editing Sees Surge in Trials, Funding, and FDA Momentum Across Six Companies

Published on Spencer Knight via LinkedIn

Multiple gene editing breakthroughs were announced in a single week, signaling strong momentum for the field. Highlights include:

• Epicrispr raised $68M to advance epigenetic therapy for FSHD

• Precision BioSciences received FDA clearance for its HBV gene editing therapy

• iECURE reported a complete clinical response for its OTC gene therapy

• Intellia received FDA Fast Track and RMAT for NTLA-2001 (ATTR amyloidosis)

• Verve got the green light to expand U.S. trials for VERVE-102, targeting PCSK9

• AccurEdit secured Orphan Drug Designation for ART001, an in vivo therapy

Spencer Knight points out that despite recent turbulence in the space, this surge in approvals, funding, and early-phase wins shows the next wave of gene editing is underway.

Read the full post on LinkedIn:

👉 Spencer Knight: HUGE week for Gene Editing

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.